Epocrates Drug Updates - Editor's Pick

March 2, 2016
Otiprio Approved for Bilateral Otitis Media

The FDA recently approved Otiprio (ciprofloxacin otic) for the treatment of bilateral otitis media in pediatric patients 6 months and older undergoing tympanostomy tube placement. Otiprio has a different route from that of existing ciprofloxacin otic products; it is given intratympanically in the ear(s) as a one-time dose following suctioning of the middle ear effusion. Otiprio consists of a thermosensitive gel that is a liquid at or below room temperature and gels when warmed.

January 19, 2016
Genvoya Approved for HIV-1 Infection

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a new fixed-dose, once-daily complete regimen for HIV-1 infection treatment in pts 12 yrs and older. Its boxed warning states that it can cause lactic acidosis and severe hepatomegaly. Genvoya contains tenofovir alafenamide, a new prodrug that appears to be associated w/ less kidney toxicity and loss in bone density than the previously approved tenofovir disoproxil, and has a different drug interaction profile.

New Drug Monographs

What is an RSS Feed?

From Wikipedia: "RSS is a simple XML-based system that allows users to subscribe to their favorite websites. Using RSS, webmasters can put their content into a standardized format, which can be viewed and organized through RSS-aware software or automatically conveyed as new content on another website."

email Subscribe by email

Enter your email address:


Delivered by FeedBurner


January 19, 2016
The Gabitril and generic tiagabine monographs have been updated to correct the pediatric dosing for adjunct treatment of partial seizures to 32 mg/day PO divided bid-qid, up to a max dose of 32 mg/day. Please update your Epocrates app regularly to ensure that you always have the latest content.